{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:47:19Z","timestamp":1761709639861},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1684\/bdc.2013.1735","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T19:58:43Z","timestamp":1565726323000},"page":"417-426","source":"Crossref","is-referenced-by-count":3,"title":["Toxicit\u00e9 cutan\u00e9e des anti-EGFR (epidermal growth factor receptor) : algorithme th\u00e9rapeutique du groupe fran\u00e7ais PROCUR"],"prefix":"10.1016","volume":"100","author":[{"given":"Claude","family":"Bachmeyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziad","family":"Reguia\u00ef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucie","family":"Peuvrel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Baptiste","family":"Bachet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9-Jean","family":"Bensadoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Ychou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Dr\u00e9no","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2013.1735_bib0005","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","article-title":"Cutaneous adverse effects with HER1\/EGFR-targeted agents: is there a silver lining?","volume":"23","author":"Perez-Soler","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1735_bib0010","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1002\/cncr.25090","article-title":"Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life","volume":"116","author":"Joshi","year":"2010","journal-title":"Cancer"},{"key":"10.1684\/bdc.2013.1735_bib0015","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000112795","article-title":"Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results","volume":"72","author":"Boone","year":"2007","journal-title":"Oncology"},{"key":"10.1684\/bdc.2013.1735_bib0020","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1684\/bdc.2013.1735_bib0025","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0959-8049(09)70044-9","article-title":"Skin toxicities of targeted therapies","volume":"45","author":"Segaert","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1684\/bdc.2013.1735_bib0030","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s00520-012-1404-0","article-title":"Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors","volume":"20","author":"Peuvrel","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1684\/bdc.2013.1735_bib0035","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1634\/theoncologist.2011-0365","article-title":"Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review","volume":"17","author":"Bachet","year":"2012","journal-title":"Oncologist"},{"key":"10.1684\/bdc.2013.1735_bib0040","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1468-3083.2011.04421.x","article-title":"Survey on the management of skin toxicity associated with EGFR inhibitors amongst French physicians","volume":"27","author":"Peuvrel","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1684\/bdc.2013.1735_bib0045","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00520-012-1451-6","article-title":"Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm","volume":"20","author":"Reguiai","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1684\/bdc.2013.1735_bib0050","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/annonc\/mdm400","article-title":"Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck","volume":"19","author":"Bernier","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2013.1735_bib0055","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/cncr.24120","article-title":"Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy","volume":"115","author":"Tejwani","year":"2009","journal-title":"Cancer"},{"key":"10.1684\/bdc.2013.1735_bib0060","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2013.1735_bib0065","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2007.12.8330","article-title":"Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects","volume":"25","author":"Gerber","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1735_bib0070","unstructured":"NCI Common Terminology Criteria for Adverse Events (CTCAE), v3.0. ctep.cancer.gov\/reporting\/ctc.html."},{"key":"10.1684\/bdc.2013.1735_bib0075","unstructured":"NCI Common Terminology Criteria for Adverse Events (CTCAE), v4. ctep.cancer.gov\/reporting\/ctc.html."},{"key":"10.1684\/bdc.2013.1735_bib0080","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00520-009-0744-x","article-title":"A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group","volume":"18","author":"Lacouture","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1684\/bdc.2013.1735_bib0085","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s00520-010-0999-2","article-title":"How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors?","volume":"19","author":"Chan","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1684\/bdc.2013.1735_bib0090","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1097\/01.BRS.0000065484.95996.AF","article-title":"Updated method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group","volume":"28","author":"van Tulder","year":"2003","journal-title":"Spine"},{"key":"10.1684\/bdc.2013.1735_bib0095","unstructured":"CEBM. http:\/\/www.cebm.net\/index.aspx?o=1025"},{"key":"10.1684\/bdc.2013.1735_bib0100","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1735_bib0105","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/cncr.23621","article-title":"Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)","volume":"13","author":"Jatoi","year":"2008","journal-title":"Cancer"},{"issue":"15s","key":"10.1684\/bdc.2013.1735_bib0110","article-title":"CYTAR: a randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients","volume":"28","author":"Deplanque","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1735_bib0115","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","article-title":"Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption","volume":"25","author":"Scope","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1735_bib0120","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1158\/1078-0432.CCR-06-2610","article-title":"Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies","volume":"13","author":"Wacker","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1684\/bdc.2013.1735_bib0125","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jaad.2006.06.034","article-title":"Treatment of gefitinib-associated folliculitis","volume":"55","author":"Matheis","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1684\/bdc.2013.1735_bib0130","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000088502","article-title":"Cetuximab-induced acne","volume":"211","author":"Molinari","year":"2005","journal-title":"Dermatology"},{"key":"10.1684\/bdc.2013.1735_bib0135","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1684\/ejd.2009.0650","article-title":"Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients","volume":"19","author":"de Noronha e Menezes","year":"2009","journal-title":"Eur J Dermatol"},{"key":"10.1684\/bdc.2013.1735_bib0140","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jaad.2009.03.046","article-title":"A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption","volume":"61","author":"Scope","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1684\/bdc.2013.1735_bib0145","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMc1003937","article-title":"Aprepitant for erlotinib-induced pruritus","volume":"363","author":"Vincenzi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2013.1735_bib0150","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1634\/theoncologist.2010-0063","article-title":"Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions","volume":"15","author":"Amitay-Laish","year":"2010","journal-title":"Oncologist"},{"key":"10.1684\/bdc.2013.1735_bib0155","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1016\/j.jaad.2009.11.589","article-title":"Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib","volume":"63","author":"Vergou","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1684\/bdc.2013.1735_bib0160","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/annonc\/mdi300","article-title":"Trichomegaly of the eyelashes following treatment with cetuximab","volume":"16","author":"Bouch\u00e9","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2013.1735_bib0165","first-page":"S22","article-title":"Clinical management of EGFRI dermatologic toxicities: the European perspective","volume":"21","author":"Segaert","year":"2007","journal-title":"Oncology (Williston Park)"},{"issue":"11 Suppl. 5","key":"10.1684\/bdc.2013.1735_bib0170","first-page":"17","article-title":"Clinical management of EGFRI dermatologic toxicities: US perspective","volume":"21","author":"Lacouture","year":"2007","journal-title":"Oncology (Williston Park)"},{"key":"10.1684\/bdc.2013.1735_bib0175","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1188\/08.CJON.283-290","article-title":"An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors","volume":"12","author":"Eaby","year":"2008","journal-title":"Clin J Oncol Nurs"},{"key":"10.1684\/bdc.2013.1735_bib0180","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/annonc\/mdm400","article-title":"Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck","volume":"19","author":"Bernier","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2013.1735_bib0185","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3747\/co.v16i1.361","article-title":"Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations","volume":"16","author":"Melosky","year":"2009","journal-title":"Curr Oncol"},{"key":"10.1684\/bdc.2013.1735_bib0190","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.gcb.2009.02.008","article-title":"Bioth\u00e9rapies cibl\u00e9es en canc\u00e9rologie digestive : prise en charge de leurs effets secondaires","volume":"33","author":"Bouch\u00e9","year":"2009","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1684\/bdc.2013.1735_bib0195","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/annonc\/mdq387","article-title":"Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion","volume":"22","author":"Potthoff","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2013.1735_bib0200","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support Care Cancer"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115303337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115303337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T17:14:31Z","timestamp":1610817271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115303337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0007455115303337"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2013.1735","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}